Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer.
The subcutaneous (H-SC) formulation of trastuzumab was demonstrated to be as effective and safe as...
Read More